From the mechanism, ANO1 inhibits ferroptosis of cancer in a phosphatidylinositol 3 kinase/protein kinase B signaling-dependent manner, promotes tumor progression by promoting tumor growth factor-B release, and promotes the recruitment of CAFs, thereby anti-tumor immunity mediated by CD8-positive T cells is weakened and resistance to immunotherapy is generated (51). The gene discussed is CD8A; the disease is cancer.